Regeneron (REGN) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Regeneron (REGN) Misses Q4 GAAP EPS Views on R&D, Pipeline Expansion, but EYLEA Shaping-Up Well - Roth Capital
February 11, 2015 8:54 AM ESTRoth Capital affirms Regeneron (Nasdaq: REGN) at Buy with a price target of $461 following Q4, FY14 results reported earlier in the week.
Analyst Joseph Pantginis noted that Q4 GAAP EPS of $0.96 compared with his estimate of $1.36. The analyst attributed the miss to continued pipeline expansion as well as growing R&D reimbursement payments to Bayer and Sanofi."
Following results, Pantginis commented, We... More
Piper Jaffray Downgrades Regeneron Pharma (REGN) to Neutral
February 10, 2015 10:54 AM ESTPiper Jaffray downgraded Regeneron Pharma (NASDAQ: REGN) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $399.72 yesterday.
... More